& Device sales reported at Bt9,926mn, growing 7.1%YoY from a higher device sale due to economic recovery boosted by government campaign early in the quarter compared to previous year which was still in the

device sales, offset by growth in all core businesses. The total revenue increased by 2.9% QoQ driven by the launch of iPhone15. Core service revenue (excluding IC and NT partnership) recorded at

enhanced device margin. AIS reported a net profit of Bt8,788mn, increasing 7.9% YoY reflecting strong operating performance, while increasing 2.5% QoQ from higher foreign exchange rate gain. 3Q24 MD&A

ปฏิบัติงำนท่ีมีกำรใช้อุปกรณ์เคลื่อนท่ี (mobile device) เพื่อเข้ำถึงระบบสำรสนเทศภำยในองค์กร และกำรปฏิบัติงำนจำกภำยนอกบริษัท (teleworking) 3.1 กรณีพนักงานท าการเชื่อมต่อ remote access จากที่บ้าน ผู้ประกอบ

, medical device business is expected to be growth at an average rate of 8.5-10.0% per year. This growth will be supported by: (i) government policy, focused on promoting investment in the sector through the

1,921 million decreased by 7% compared to the previous year. It derived from: • Revenues from sales and services of medical device business for the year 2019 were Baht 1,798 million decreased by 3% in

and appraising assets, as well as extensive nationwide network allow BAM to manage both NPLs and NPAs effectively in the way that would maintain revenue growth 2. Considerations 2.1 During the slowdown

 (minute/s Postpaid  Prepaid  Blended  VOU (GB/data s Postpaid  Prepaid  Blended  Device Penetrat 4G‐handset   Fixed Broadban FBB subscri FBB net add FBB ARPU (   1H17 Snap For 1H17, AIS  (excluding  IC

% -2.4% Prepaid 113 92 86 -24% -6.5% Blended 138 118 112 -19% -5.1% VOU (GB/data sub/month) Postpaid 14.4 16.6 17.0 18% 2.3% Prepaid 10.3 11.1 13.8 34% 23% Blended 11.4 12.7 14.7 29% 16% Device Penetration

appropriate by Dhipaya Bodin as a joint venture. It will benefit potential shareholders in the medical device and distribution business. The current production and distribution line is Blood Line with a